Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1548550 | 0.82 | GRIN2D (0.50) | EPHX2ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL1548111 | 0.77 | EPHX2 (0.42) | EPHX2ALDH1A1MEN1KMT2A | |
| SCHEMBL1549046 | 0.77 | LMNA (0.45) | EPHX2SMN1; SMN2P2RX7MEN1KMT2A | |
| SCHEMBL23023223 | 0.75 | MEN1 (0.71) | EPHX2ALDH1A1SMN1; SMN2P2RX7MEN1 | |
| SCHEMBL1549048 | 0.75 | MEN1 (0.71) | EPHX2ALDH1A1SMN1; SMN2P2RX7MEN1 | |
| SCHEMBL17598268 | 0.75 | MEN1 (0.71) | EPHX2ALDH1A1SMN1; SMN2P2RX7MEN1 | |
| SCHEMBL30195756 | 0.72 | SIGMAR1 (0.48) | EPHX2ALDH1A1SMN1; SMN2P2RX7 | |
| SCHEMBL15149709 | 0.70 | EPHX2 (0.52) | EPHX2ALDH1A1SMN1; SMN2P2RX7MEN1 | |
| Rimantadine SCHEMBL5663543 | 0.69 | SLC22A2 (0.67) | EPHX2ALDH1A1SMN1; SMN2P2RX7 | |
| SCHEMBL12797027 | 0.68 | NPC1 (0.53) | EPHX2ALDH1A1P2RX7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874282-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF CNS DISORDERS | Adamas Pharmaceuticals, Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006121560-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF CNS DISORDERS | ADAMAS PHARMACEUTICALS, INC. (US) | 2006-11-16 | — | — | WO | disclosed |